Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals, a biopharmaceutical company, has appointed Elkan Gamzu as its new president and CEO and as a member of the board. Dr Gamzu has served in the role of interim CEO of Epix since July 2008.
Subscribe to our email newsletter
Dr Gamzu has more than 35 years of pharmaceutical and biotechnology industry experience and has held a number of senior executive positions in those industries including CEO of Pharmos; vice president of project management leadership of Millennium Pharmaceuticals; CEO of Cambridge Neuroscience; vice president of drug development of Warner-Lambert and senior positions with Hoffman-La Roche.
Dr Gamzu is a graduate of Hebrew University in Jerusalem, and has MA and PhD degrees in experimental and physiological psychology from the University of Pennsylvania.
Frederick Frank, chairman of the board of directors of Epix, said: “After a comprehensive review of Elkan’s performance over the past seven months, the board concluded that Elkan is the right candidate to continue to lead Epix as the company focuses on executing its core clinical and business development strategies.”